COCRYSTALS OF AN ADENOSINE A2B RECEPTOR ANTAGONIST

Cocrystals of an adenosine A2B receptor antagonist, 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3,7-dihydro-1H-purine-2,6-dione, methods of preparing the cocrystals, pharmaceutical compositions of the cocrystals, and uses of the cocrystals are disclosed. L'invention conce...

Full description

Saved in:
Bibliographic Details
Main Authors OSTOVIC, Drazen, KARABORNI, Sami, LIU, Jiwen
Format Patent
LanguageEnglish
French
Published 10.03.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Cocrystals of an adenosine A2B receptor antagonist, 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3,7-dihydro-1H-purine-2,6-dione, methods of preparing the cocrystals, pharmaceutical compositions of the cocrystals, and uses of the cocrystals are disclosed. L'invention concerne des co-cristaux d'un antagoniste du récepteur de l'adénosine A2B, 3-éthyl-1-propyl-8-(1- (3- (trifluorométhyl)benzyle)-1H-pyrazol-4-yl)-3,7-dihydro-1H-purine-2,6-dione, des méthodes de préparation des co-cristaux, des compositions pharmaceutiques des co-cristaux et des utilisations des co-cristaux.
Bibliography:Application Number: WO2021US49011